Gadobutrol

CHEMBL2218860 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
604.7 g/mol
LogP
Phase
4

This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

आणविक भार

604.7000 g/mol

TPSA

194.00 Ų

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@H](CO)[C@@H](CO)O)CC(=O)[O-].[Gd+3]

InChI

InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1

Molecular Formula

C18H31GdN4O9

HBD / HBA

3 / 13

घूर्णनीय बंधन

7

भारी परमाणु

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Gadobutrol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218860. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6102852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.